CPC A61K 47/34 (2013.01) [A61K 9/70 (2013.01); A61L 15/44 (2013.01); A61L 27/18 (2013.01); A61L 27/54 (2013.01); D01D 5/003 (2013.01); D01F 1/10 (2013.01); D01F 6/625 (2013.01); D02J 13/00 (2013.01); D02J 13/003 (2013.01); D04H 1/728 (2013.01); A61K 31/455 (2013.01); A61K 2300/00 (2013.01); A61L 2300/434 (2013.01); A61L 2300/602 (2013.01); D01F 6/68 (2013.01)] | 5 Claims |
1. A drug delivery system comprising: a first electrospun poly-L-lactic acid (PLLA) fiber scaffold (EFS) having a first crystallinity percentage; a second PLLA EFS having a second crystallinity percentage different than that of the first PLLA EFS; and at least one active pharmaceutical ingredient (API), wherein the at least one API is released from the first PLLA EFS at a first rate and the at least one API is released from the second PLLA EFS at a second rate different than the first release rate upon administration of the drug delivery system to an individual,
wherein the first PLLA EFS is heat treated at a first temperature and the second PLLA EFS is heat treated at a second temperature, and
wherein the first temperature is between about 50° C. and about 60° C. and the second temperature is at least 80° C.
|